Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Makes Deal With Huya For Access To Chinese Drugs

This article was originally published in PharmAsia News

Executive Summary

Organon has signed a collaborative deal with Huya Bioscience, a San Diego-based company that promises to link the Dutch drug maker with the owners of new compounds being developed in China
Advertisement

Related Content

Schering-Plough Teams Up With Huya To Identify Novel Compounds In China
Schering-Plough Teams Up With Huya To Identify Novel Compounds In China
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
Huya’s Foreign Clinical Advisory Team Includes Topol, Kowey
Huya’s Foreign Clinical Advisory Team Includes Topol, Kowey
Pfizer Ends Asenapine Collaboration With Organon
Advertisement
UsernamePublicRestriction

Register

SC065642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel